Unlock instant, AI-driven research and patent intelligence for your innovation.
Application of M1 combined M2 type macrophage factor as biomarker in diagnosis and treatment monitoring of rheumatoid arthritis
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A macrophage and rheumatoid technology, applied in the field of molecular biology of rheumatic immune diseases, can solve the problems of lack of specific diagnosis of rheumatoid arthritis, evaluation of inflammation degree of treatment monitoring, etc., and achieve high throughput and high data reproducibility. , the effect of accurate diagnosis
Active Publication Date: 2022-06-07
FIRST AFFILIATED HOSPITAL OF ANHUI UNIV OF CHINESE MEDICINE
View PDF17 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0005] In view of the lack of diagnostic markers for rheumatoid arthritis at present, the present invention provides a use of M1 combined with M2 macrophage cytokines as biomarkers in the diagnosis and treatment monitoring of rheumatoid arthritis, which is used to solve the problem of prior art There is a lack of use of M1 combined with M2 macrophage cytokines as biomarkers for specific diagnosis, treatment monitoring, and evaluation of inflammation in rheumatoid arthritis.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0029] 1. Preparation of samples and standards
[0030] Standards and samples are handled as follows:
[0032] There were 60 blood samples, including 30 healthy control (HC) group and 30 RA group.
[0033] Serum sample preparation: 10,000rpm, centrifuge for 10min, take the supernatant, dilute it twice with Calibrator DiluentRD6-52, that is, add 40ul RD6-52 to the 40ul sample, and finally take 50μL of the diluted sample for detection.
[0034] (2) Standard preparation
[0035]To the standard bottle, add the corresponding amount of diluent Calibrator Diluent RD6-52, turn it upside down several times, place it on a low-speed horizontal shaker for 15 min, and label it as a recombinant standard solution (Standard Cocktail). Prepare 9 EP tubes marked as S1, S2, S3, S4, S5, S6, S7, S8, Blank. 500 μL of the recombinant standard solution was added to the EP tube denoted S1, and 200 ul of the dilution (Calibrator Diluent RD6-52) was added to the remai...
Embodiment 2
[0061] Test results
[0062] 1. Expression of M1-type cytokine IL-1R1 in RA patients
[0063] Compared with the healthy control group (HC), the expression of M1-type cytokine IL-1R1 in the rheumatoid arthritis patient group (RA) was significantly increased (P figure 2 shown.
[0064] 2. Expression of M1-type cytokine IFN-γ in RA patients
[0065] Compared with the healthy control group (HC), the expression of M1 cytokine IFN-γ in the rheumatoid arthritis patient group (RA) was significantly increased (P image 3 shown.
[0066] 3. Expression of M1-type cytokine iNOS2 in RA patients
[0067] Compared with the healthy control group (HC), the expression of the M1-type cytokine iNOS2 in the rheumatoid arthritis patient group (RA) was significantly increased (P Figure 4 shown.
[0068] 4. Changes of M2-type cytokine MRC1 expression in RA patients
[0069] Compared with the healthy control group (HC), the expression of M2-type cytokine MRC1 in the rheumatoid arthritis patient gro...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention relates to application of M1 combined M2 type macrophage factors as biomarkers in diagnosis and treatment monitoring of rheumatoid arthritis. The problems that in the prior art, specific diagnosis, treatment monitoring, inflammation degree evaluation and the like of rheumatoid arthritis cannot be carried out by using M1 and M2 type macrophage factors as biomarkers are solved. Experiments prove that the M1 type macrophage factors IL-1R1, IFN-gamma and iNOS2 combined with the M2 type macrophage factor MRC1 can be used as diagnosis indexes of rheumatoid arthritis, so that the diagnosis result is more accurate; on the other hand, the invention further provides M1 type macrophage factors IL-1R1, IFN-gamma and iNOS2, and the M1 type macrophage factors and M2 type macrophage factors MRC1 can be combined to serve as an index for evaluating the severity of rheumatoid arthritisinflammation. Therefore, the kit can be better used for diagnosis, prognosis evaluation and treatment monitoring of rheumatoid arthritis.
Description
technical field [0001] The invention belongs to the field of molecular biology of rheumatoid immune diseases, in particular to the use of M1 combined with M2 macrophage factor as a biomarker in the diagnosis and treatment monitoring of rheumatoid arthritis. Background technique [0002] Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint synovitis and bone destruction. The inflammatory response in RA exacerbates joint and bursa destruction resulting in joint deformity and loss of function. RA "inflammatory polarization" can secrete a large number of pro-inflammatory cytokines and chemokines, activate fibroblasts and osteoclasts, accelerate the body's inflammatory response, and cause joint damage. Macrophages can produce a variety of pro-inflammatory cytokines and chemokines to participate in the pathogenesis of RA. Macrophages exhibit different phenotypes and functions under the induction of different factors, namely M1-type and M2-type macrophages, w...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More